It’s been a while since the first batch of Covid-19 vaccination was distributed throughout the United Kingdom (UK)
by Koketso Ramotsila
In the United Kingdom, BNT162b2 mRNA and ChAdOx1 nCOV-19 adenoviral vector vaccines have been swiftly carried out. In their healthcare worker (HCW) cohort study of staff receiving regular asymptomatic testing, they identified some variables related with vaccination coverage for both vaccines and demonstrated the immunization efficacy of the BNT162b2 mRNA vaccine.
This SIREN study arose back in December 2020 when infections were flooding at the UK. The SIREN project is basically a prospective cohort study including publicly financed hospitals and their employees.
At two-week intervals, baseline risk factors, vaccination status (from 8-Dec-2020 to 2-Feb-2021), and symptoms were documented, as well as all SARS-CoV-2 polymerase chain reaction (PCR) and antibody test findings.
A Poisson distribution was used in a mixed effect model. To an extent they evaluated the effects of the BNT162b2 vaccination on all infections, a mixed effect proportional hazards frailty model with a Poisson distribution which was used to compute hazard ratios to compare time to infection in unprotected and vaccinated patients. We understand that a Poisson distribution is a probability distribution that can be used to show how many times an event is likely to occur within a specified period of time.
On May 2, 2021, vaccine coverage was 89 percent. Prior infection, being under 35 years old, being from a minority ethnic group, porters/security guards, or a midwife were all linked to much poorer coverage. The BNT162b2 vaccination successfully protects both symptomatic and asymptomatic illness, according to a research. This group was vaccinated while B1.1.7 was the prevalent variation in circulation, demonstrating efficacy against it. Even fans are able occupy football matches in the UK. Did the available vaccines in South Africa produce similar successful results?
Hall V, Foulkes S, Saei A, et al. Effectiveness of BNT162b2 mRNA vaccine against infection and COVID401 19 vaccine coverage in healthcare workers in England, multicentre prospective cohort study (the SIREN 402 study).